Cargando…
Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?
Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation are locally delivered to tumor cells, while the surrounding healthy tissue is minimally affected. This therapeutic strategy relies on radiopharmaceuticals made of medically relevant radionuclides chelated by...
Autores principales: | Pallares, Roger M., Abergel, Rebecca J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812962/ https://www.ncbi.nlm.nih.gov/pubmed/36619636 http://dx.doi.org/10.3389/fmed.2022.1020188 |
Ejemplares similares
-
Clinical chorioamnionitis: where do we stand now?
por: Lukanović, David, et al.
Publicado: (2023) -
Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals
in the Context of SARS-CoV-2
por: Pallares, Roger M., et al.
Publicado: (2021) -
Design and analysis of umbrella trials: Where do we stand?
por: Ouma, Luke O., et al.
Publicado: (2022) -
Artificial Intelligence Applications in Dermatology: Where Do We Stand?
por: Gomolin, Arieh, et al.
Publicado: (2020) -
Assessment of Liver Function With MRI: Where Do We Stand?
por: Río Bártulos, Carolina, et al.
Publicado: (2022)